108.44
전일 마감가:
$109.09
열려 있는:
$109.115
하루 거래량:
4.59M
Relative Volume:
0.50
시가총액:
$134.89B
수익:
$28.73B
순이익/손실:
$5.97B
주가수익비율:
22.83
EPS:
4.75
순현금흐름:
$9.84B
1주 성능:
+0.67%
1개월 성능:
+1.97%
6개월 성능:
+17.35%
1년 성능:
+69.60%
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
GILD을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
GILD
Gilead Sciences Inc
|
108.44 | 134.00B | 28.73B | 5.97B | 9.84B | 4.75 |
![]()
LLY
Lilly Eli Co
|
719.39 | 650.81B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
152.43 | 368.56B | 89.33B | 21.81B | 18.57B | 8.99 |
![]()
ABBV
Abbvie Inc
|
183.09 | 321.13B | 57.37B | 4.20B | 15.39B | 2.35 |
![]()
NVS
Novartis Ag Adr
|
111.87 | 222.75B | 53.22B | 12.86B | 14.85B | 6.39 |
![]()
NVO
Novo Nordisk Adr
|
68.60 | 303.04B | 43.59B | 15.04B | 10.74B | 3.3766 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
2025-03-04 | 재확인 | Oppenheimer | Outperform |
2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2024-12-10 | 재개 | BofA Securities | Buy |
2024-11-15 | 개시 | Wolfe Research | Outperform |
2024-11-14 | 개시 | Citigroup | Buy |
2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2024-10-17 | 개시 | Bernstein | Outperform |
2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2024-05-01 | 재확인 | Maxim Group | Buy |
2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
2023-11-09 | 개시 | Deutsche Bank | Hold |
2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
2023-09-06 | 개시 | HSBC Securities | Reduce |
2023-07-24 | 재확인 | Barclays | Equal Weight |
2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2023-04-28 | 재개 | Piper Sandler | Overweight |
2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2022-12-13 | 재개 | BofA Securities | Neutral |
2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
2022-10-28 | 재확인 | Cowen | Outperform |
2022-10-28 | 재확인 | JP Morgan | Overweight |
2022-10-28 | 재확인 | Jefferies | Buy |
2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
2022-10-28 | 업그레이드 | Truist | Hold → Buy |
2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
2022-02-02 | 재확인 | BofA Securities | Neutral |
2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
2022-02-02 | 재확인 | Truist | Hold |
2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
2022-01-28 | 업그레이드 | Argus | Hold → Buy |
2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2021-12-09 | 재개 | Wells Fargo | Equal Weight |
2021-12-06 | 개시 | Goldman | Neutral |
2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2021-11-19 | 재개 | Piper Sandler | Neutral |
2021-10-20 | 재개 | Cowen | Outperform |
2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
2020-10-28 | 개시 | UBS | Neutral |
2020-09-30 | 재개 | Jefferies | Buy |
2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
2020-07-31 | 재확인 | Credit Suisse | Neutral |
2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
2020-07-31 | 재확인 | Piper Sandler | Overweight |
2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
2020-07-31 | 재확인 | SunTrust | Hold |
2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Gilead Sciences and Kite Pharma To Announce Transformative - CSRwire
Gilead Sciences’ SWOT analysis: HIV giant faces oncology growth, patent cliff - Investing.com Nigeria
ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs - insights.citeline.com
Gilead Ready To Go After Hepatitis D Again - insights.citeline.com
Gilead Sciences' Best Days May Be AheadHere's Why (NASDAQ:GILD) - Seeking Alpha
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer - Yahoo Finance
Gilead’s Phase III trial for breast cancer therapy meets primary goal - Clinical Trials Arena
Gilead Sciences, Inc. (GILD)’s Breast Cancer Study Success Drives Investor Optimism Amid Broader Market Slump - MSN
Gilead says Trodelvy ASCENT-03 study meets primary endpoint - The Pharma Letter
Gilead announces ASCENT-03 study meets primary endpoint - Yahoo Finance
Gilead Sciences (NasdaqGS:GILD) Announces Promising Phase 3 Results For Trodelvy In Breast Cancer - simplywall.st
Gilead (GILD) to Acquire HOOK for $10 million - Insider Monkey
Gilead Sciences (GILD) Achieves Key Trial Milestone with Trodelv - GuruFocus
After Keytruda combo win, Gilead's Trodelvy meets the mark in solo breast cancer trial - Fierce Pharma
Gilead (GILD) Announces Promising Results from Trodelvy Study | - GuruFocus
Gilead Sciences Says Trodelvy Met Primary Endpoint in Phase 3 Breast Cancer Trial - marketscreener.com
Gilead posts trial win for Trodelvy in breast cancer (GILD) - Seeking Alpha
Gilead (GILD) Announces Promising Results from Trodelvy Study | GILD Stock News - GuruFocus
ASCENT-03Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors - marketscreener.com
Gilead Sciences (GILD) announces positive data from Phase 3 Trodelvy study - StreetInsider
ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors - Business Wire
Gilead records another pivotal study success for Trodelvy in first-line TNBC - FirstWord Pharma
Sector Update: Health Care Stocks Softer Late Afternoon - marketscreener.com
Sector Update: Health Care Stocks Retreat Thursday Afternoon - marketscreener.com
HOOKIPA to Sell HBV, HIV Program Assets to Gilead; Shares Rise - marketscreener.com
Gilead (GILD) Experiences Significant Increase in Bearish Options Activity | GILD Stock News - GuruFocus
Gilead Sciences to Acquire HOOKIPA Pharma Assets for $10M - GuruFocus
Hookipa stock gains as Gilead eyes assets (HOOK:NASDAQ) - Seeking Alpha
Gilead pays partner Hookipa $10M to take over HBV, HIV therapeutic vaccine programs - Fierce Biotech
Hookipa Pharma Sells Assets to Gilead Sciences - TipRanks
What Analysts Are Saying About Gilead Sciences Stock - Benzinga
Tomas Cihlar, Gilead Sciences, Named to TIME’s List of 100 Most Influential People in the World for HIV Research - CSRwire
Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance
Gilead Sciences (GILD) Receives Hold Rating from Needham | GILD Stock News - GuruFocus
Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now? - Zacks Investment Research
Tomas Cihlar, Gilead Sciences, Named to TIME’s List of 10 - 3BL Media
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Unusual Options Alert: The Smart Money Is Piling Into Gilead Sciences (GILD) - Barchart.com
Gilead Sciences: Buy Rating Affirmed Amid Promising Lenacapavir Approval and Market Expansion - TipRanks
Gilead Sciences discovers new PRMT5 inhibitors - BioWorld MedTech
Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA - Yahoo Finance
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus
Gilead Sciences (GILD) is Flashing a Quant Signal That Wall Street is Ignoring - Money Morning
Gilead Sciences: Bringing PBC Into Focus Through Art of Patient Stories - CSRwire
Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and E - BioSpace
Does Gilead's drug lenacapavir have the power to end the AIDS epidemic?San Francisco Business Times - The Business Journals
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Th - GuruFocus
Gilead And Kite Announce Presentation Of Transformative Data In 1L Metastatic Triple-Negative Breast Cancer, Updated Results In Multiple Myeloma And Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer At 2025 ASCO And - marketscreener.com
Does Gilead's latest PreP drug lenacapavir have the power to end the AIDS epidemic?San Francisco Business Times - The Business Journals
Upcoming Meeting for GILD in Foster City | GILD Stock News - GuruFocus
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
길리어드 사이언스 주식 (GILD) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Mercier Johanna | Chief Commercial Officer |
May 22 '25 |
Sale |
107.52 |
28,000 |
3,010,564 |
121,152 |
자본화:
|
볼륨(24시간):